Nonoxinol-9 liposomal - Novavax

Drug Profile

Nonoxinol-9 liposomal - Novavax

Alternative Names: Nonoxinol-9 Novasome®; Nonoxynol-9 liposomal - Novavax; Nonoxynol-9 Novasome®

Latest Information Update: 30 Jul 2002

Price : $50

At a glance

  • Originator Novavax
  • Developer National Institutes of Health (USA); Novavax
  • Class Spermicidal contraceptives; Surfactants
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Contraception

Most Recent Events

  • 30 Jul 2002 Added WHO report results regarding spermicides containing nonoxynol-9 to the overview section
  • 08 Apr 1999 Phase-I clinical trials for Contraception in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top